Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy
- 31 March 2026
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 219, 111519
Abstract
No abstract availableKeywords
Funding Information
- Institut Kanser Negara (P30 CA008748)
- National Cancer Institute (P30 CA008748)
This publication has 14 references indexed in Scilit:
- Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directionsCancer Treatment Reviews, 2025
- Advances in the treatment of KRASG12C mutant non–small cell lung cancerCancer, 2025
- Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancerThe Oncologist, 2025
- The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?Lung Cancer, 2024
- Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice GuidelinesLung Cancer, 2023
- Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung CancerJournal of Thoracic Oncology, 2023
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a
KRAS
G12C
MutationNew England Journal of Medicine, 2022
- Sotorasib for Lung Cancers with KRAS p.G12C MutationNew England Journal of Medicine, 2021
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerJAMA Oncology, 2017
- Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic reviewCancer Treatment Reviews, 2017